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Telomere length as a predictor of response to Pioglitazone in
patients with unremitted depression: a preliminary study
N Rasgon1,2,3, KW Lin1,2,3, J Lin1,2,3, E Epel1,2,3 and E Blackburn1,2,3
We studied peripheral leukocyte telomere length (LTL) as a predictor of antidepressant response to PPAR-γ agonist in patients with
unremitted depression. In addition we examined correlation between LTL and the insulin resistance (IR) status in these subjects.
Forty-two medically stable men and women ages 23–71 with non-remitted depression participated in double-blind placebo-
controlled add-on of Pioglitazone to treatment-as-usual. Oral glucose tolerance tests were administered at baseline and at
12 weeks. Diagnostic evaluation of psychiatric disorders was performed at baseline and mood severity was followed weekly
throughout the duration of the trial. At baseline, no differences in LTL were detected by depression severity, duration or chronicity.
LTL was also not significantly different between insulin-resistant and insulin-sensitive subjects at baseline. Subjects with longer
telomeres exhibited greater declines in depression severity in the active arm, but not in a placebo arm, P= 0.005, r=− 0.63, 95%
confidence interval (95% CI) = (−0.84,− 0.21). In addition, LTL predicted improvement in insulin sensitivity in the group overall and
did not differ between intervention arms, P= 0.036, r=− 0.44, 95% CI = (−0.74,0.02) for the active arm, and P= 0.026, r=− 0.50, 95%
CI = (−0.78,− 0.03) for the placebo arm. LTL may emerge as a viable predictor of antidepressant response. An association between
insulin sensitization and LTL regardless of the baseline IR status points to potential role of LTL as a non-specific moderator of
metabolic improvement in these patients.
Translational Psychiatry (2016) 6, e709; doi:10.1038/tp.2015.187; published online 5 January 2016
INTRODUCTION
Leukocyte telomere length (LTL) provides an index of cellular
aging that can predict incidence of age-related diseases, such as
cardiovascular disease (CVD) and type 2 diabetes.1–6 Insulin
resistance (IR), a highly prevalent metabolic abnormality, signifi-
cantly increases risk for CVD and type 2 diabetes.7,8 Previous
studies have described associations between shortened telomeres
and depression,9,10 as well as chronic mood and anxiety
disorders11 although not all studies support the possibility that
LTL is a predictor of depression.
Depressive disorders are among most prevalent psychiatric
illnesses and are highly co-morbid with CVDs, diabetes among
others.12–14 While individual prevalence for both IR and depres-
sion are rapidly increasing,12,13 the non-random co-occurrence of
IR and depression is striking.14 Yet the understanding of this
relationship is limited. Following our early postulate that IR
is a part of—and may contribute to—the pathophysiology of
depression,15,16 we reported an antidepressant response to an
insulin-sensitizing agent, metformin,17 and to the PPAR-γ agonists
rosiglitazone18 and Pioglitazone19 in patients with unremitted
depression.
In addition to the metabolic dysfunction of IR, when compared
with non-depressed individuals, patients with major depression
have been found to exhibit all of the cardinal features of
inflammation.20,21 Because increased inflammatory markers at
baseline predict an antidepressant response,22–24 reducing
inflammation may also augment response to psychotropic
medications. Few studies to date have investigated an association
between LTL and therapeutic response in depression, reporting
both presence25 and absence26 of such an association. No studies,
however, assessed LTL and response to treatment with PPAR-γ
agonists. This report is a part of parent study (under review)
of an antidepressant response to an adjuvant PPAR-γ agonist,
Pioglitazone, in patients with unremitted depression.19 Here we
aimed to assess LTL as a predictor of antidepressant response to
Pioglitazone in groups of IR and insulin-sensitive (IS) subjects
using surrogate markers of IR.
MATERIALS AND METHODS
The Stanford University Institutional Review Board approved the current
study in its entirety. All participants provided informed consent prior to
study enrollment after they received detailed information regarding all
study procedures, potential side effects of study medication, risks and
benefits of participation, and contact personnel in case of questions or
concerns. Study participants were recruited through collaboration with
established investigators in the area of adult depression within the
Department of Psychiatry & Behavioral Sciences at Stanford University, as
well as community health providers. In addition, participants were
recruited through advertisements in local newspapers and clinical trial
recruitment websites.
Inclusion criteria included being between 21 and 75-years-old, having a
body mass index of 18.5 to 40 kg/m2, having at least 12 years of education,
having a history of depression with at least 8 weeks of stable treatment-as-
usual for depression. We did not exclude subjects on a basis of a type of
medication(s) used in treatment of depression, as our primary goal was to
evaluate antidepressant qualities of adjunctive Pioglitazone.
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Exclusion criteria included a history of liver dysfunction, electroconvul-
sive therapy within the previous 6 months, diagnosis of possible or
probable dementia or evidence of cognitive decline, history of Type I or
Type II diabetes, history of significant CVD or myocardial infarction,
cerebrovascular disease, pulmonary disease, cancer, untreated hypo-
thyroidism, unstable or untreated hypertension, known osteoporosis or
prior history of non-traumatic fracture, history of a neurological disorder or
evidence of neurologic or other physical illness that could produce
cognitive deterioration.
Forty-two medically stable men and women ages 23–71 with
non-remitted depression were enrolled. Among enrolled participants,
metabolic dysfunction ranged across the insulin sensitivity spectrum,
including IS, IR and/or IR with hyperglycemia, for example, prediabetes.
Thirty-seven participants completed the study, including 9 males and 33
females. This includes 5 males and 17 females in the active arm, and 4
males and 16 in the placebo arm. Mean education of the whole group was
16.07 years, 15.91 for the active arm and 16.25 for the placebo arm. Five
participants withdrew from the study; two moved, one withdrew due to a
side effect (edema) of treatment with Pioglitazone and two did not specify
a reason for withdrawal.
Randomized controlled trial design and randomization
This randomized controlled trail consisted of a parallel design in which
50% of participants were allocated to 12 weeks of treatment with 30mg
per day of Pioglitazone and 50% of participants were randomized to
12 weeks treatment with placebo pill. Random allocation was generated by
use of a random number generator that assigned half of the subjects’
identification numbers to each study condition. A staff member of the
Stanford University Department of Psychiatry and who did not participate
in the implementation of the study performed randomization and
maintenance of the unblinded study list. Active and placebo medication
were bottled and labeled with participant identification numbers by this
unblinded staff person according to randomized assignment. Study
investigators, coordinators, raters and clinical laboratory staff remained
blinded to subject treatment assignments throughout their participation in
the study.
Statistical analysis
Statistical analyses were conducted using Statistical Analysis System 9.4
(SAS Institute, Cary, NC, USA). Missing metabolic data, including telomere
length, fasting plasma glucose and oral glucose tolerance test (OGTT) were
imputed using fully conditional specification regression imputation.27
Hamilton score T-tests were conducted to assess baseline differences
between treatment arms. Correlations and linear regression analysis were
used to assess for the association between baseline telomere length and
treatment response, including change in HDRS-21 and change in OGTT.
Reliability of using change scores for the HDRS-21 scale was tested using
the reliable change index.
Clinical assessment
Clinical assessment consisted of a physical examination and laboratory
tests, including measures of height and weight, an OGTT, fasting plasma
glucose and fasting plasma insulin. Other data collected included current
medications and family medical history. All clinical and laboratory tests
were repeated at the end of treatment (Week 12) with the exception of the
genetic sample.
Oral glucose tolerance test
The OGTT measures individual ability to metabolize glucose and can
distinguish between normal patterns and the patterns of diabetes and IR.28
We chose this test over other direct and surrogate measures of IR, such as
the insulin suppression test or the hyperinsulinemic euglycemic clamp,
because of its relatively short duration and participant tolerability.
Furthermore, it does not involve administration of pharmacological agents,
as do other assessments of glucose or insulin tolerance. Participants
undergoing OGTT began in a fasting state (no food or drink except water
for at least 10 h). Blood samples were obtained to measure baseline
glucose and insulin concentrations, followed by administration of 75mg of
oral glucose, after which additional samples were obtained at +30, +60,
+90 and +120min. A meal was given to each participant immediately
following completion of the procedure.
IR was defined by surrogate markers according to the following
criteria:29
1. Fasting plasma glucose ⩾ 100mg dl− 1.
2. An OGTT at 120min ⩾ 140mg dl− 1.
3. Fasting plasma insulin ⩾ 15 mIU/L.
4. Homeostatic model assessment-insulin resistance (HOMA-IR) 43.8.
Psychiatric assessment
The psychiatric examination at screening included the Structured Clinical
Interview for DSM-IV (SCID),30 the 17-item Hamilton Depression Rating
Scale (HDRS-21)31 and the mini–mental state examination.32 Unremitted
depression status was characterized by a 21-item HDRS (HDRS-21) score
⩾ 8 following at least 8 weeks of stable treatment-as-usual for their
depression. We will not exclude subjects on the basis of a type of
medication/s used in treatment of depression, as our primary goal is to
evaluate antidepressant qualities of adjunctive Pioglitazone. Administration
of the HDRS-21 was repeated at each interim visit (Weeks 2, 4, 6 and 8) and
at the end of treatment (Week 12). The mini–mental state examination, a
brief measure of global cognitive functioning was used to screen out
current cognitive impairment. Among participants, 15 were identified as
having 3 or fewer lifetime episodes of depression, 15 were identified as
having 4 or more episodes and 12 subjects were unsure of the number of
episodes. The mean duration of the current depressive episode was
397.21 days (s.d. = 827.59). Twelve subjects were unable to estimate the
duration of the current episode, or identified it as duration greater than 10
years. A board certified neuropsychologist who was blinded to the
treatment assignment completed psychiatric tests and evaluations.
LTL measurement
Total genomic DNA was purified using QIAamp DNA blood Mini
kit (QIAGEN, Venlo, The Netherlands, Cat#51106) from whole blood stored
at − 80 °C and quantified by measuring OD260. The telomere length assay
is adapted from the published original method by Cawthon.33,34 The
telomere thermal cycling profile consists of: cycling for T(telomic) PCR:
96 °C for 1 min; denature at 96 °C for 1 s, anneal/extend at 54 °C for 60 s,
with fluorescence data collection, 30 cycles.
Cycling for S (single-copy gene) PCR: PCR: 96 °C for 1 min; denature at
95 °C for 15 s, anneal at 58 °C for 1 s, extend at 72 °C for 20 s, 8 cycles;
followed by denature at 96 °C for 1 s, anneal at 58 °C for 1 s, extend at 72 °C
for 20 s, hold at 83 °C for 5 s with data collection, 35 cycles.
The primers for the telomere PCR are tel1b (5′-CGGTTT(GTTTGG)5GTT-3′),
used at a final concentration of 100 nM, and tel2b (5′-GGCTTG(CCTTAC)5
CCT-3′), used at a final concentration of 900 nM. The primers for the single-
copy gene (human beta-globin) PCR are hbg1 (5′-GCTTCTGACACAA
CTGTGTTCACTAGC-3′), used at a final concentration of 300 nM, and hbg2
(5′-CACCAACTTCATCCACGTTCACC-3′) used at a final concentration of 700
nM. The final reaction mix contains 20mM Tris-HCl, pH 8.4; 50mM KCl; 200
mM each dNTP; 1% DMSO; 0.4× Syber Green I; 22 ng Escherichia coli
DNA per reaction; 0.4 U of Platinum Taq DNA polymerase
(Invitrogen, Waltham, MA, USA). To control for inter-assay variability, eight
control DNA samples are included in each run. In each batch, the average
telomere to single gene copy ratio T/S ratio of each control DNA is divided
by T/S for the same DNA from 10 runs to get a normalizing factor.34 This is
done for all eight samples and the average normalizing factor for all eight
samples is used to correct the participant DNA samples to get the final T/S
ratio. The T/S ratio for each sample was measured twice. When the
duplicate T/S value and the initial value vary by47%, the sample was run
the third time and the two closest values were reported. The coefficient of
variation for this study is 2.4%.) per 11 μl reaction; 6 ng of genomic DNA.
Tubes containing 26, 8.75, 2.9, 0.97, 0.324 and 0.108 ng of a reference DNA
(from the Hela cancer cell line) are included in each PCR run so that the
quantity of targeted templates in each research sample can be determined
relative to the reference DNA sample by the standard curve method. The
same reference DNA was used for all PCR runs.33
RESULTS
Forty-two individuals with unremitted depressive disorder were
evaluated for LTL at baseline. Their demographic and clinical
characteristics are presented below (Table 1). LTL was not
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correlated with HDRS-21 at score baseline (P= 0.29, r= 0.17, 95%
CI =− 0.14,0.45). Neither did LTL differ between IR and IS subjects
at baseline.
Baseline age and LTL were correlated at baseline assessment in
the whole group (P= 0.005, r=− 0.42, 95% CI =− 0.64,− 0.13) and
the active arm (P= 0.003, r=− 0.60, 95% CI =− 0.81,− 0.23), but not
the placebo arm (P= 0.93, r=− 0.002, 95% CI =− 0.46, 0.43). This
may be due to the fact that subjects in the placebo group are
significantly younger than subjects in the active arm (Table 1). In
the whole sample, age and LTL were correlated in subjects older
than 45 (P= 0.04 r=− 0.42, 95% CI =− 0.70., −0.01), but not those
younger than 45 (P= 0.52, r= 0.16, 95% CI =− 0.33, 0.58).
Subjects with longer telomeres exhibited greater declines in
depression severity in the active arm (P= 0.005, r=− 0.63, 95%
CI =− 0.84,− 0.21) (Figure 1), but not in a placebo arm (P= 0.36,
r= 0.27, 95% CI =− 0.32, 0.69). There was no significant interaction
between treatment arm and the LTL as predictors of HDRS-21
treatment response.
Conversely, LTL predicted improvement in OGTT in the group
overall, and did not differ between intervention arms (P= 0.036,
r=− 0.44, 95% CI =− 0.74, 0.02) for the active arm, and P= 0.026,
r=− 0.50, 95% CI =− 0.78, − 0.03) for placebo arm. There was no
significant interaction between treatment arm and the LTL as
predictors of OGTT treatment response.
Age and age group (dichotomized at 45 years) were added to
generalized linear models to adjust for the potentially confound-
ing effect of age on the relationship between LTL and HDRS-21or
OGTT outcomes. Neither covariate was significant in any model.
All associations in age and age-group-adjusted models remained
significant, with the exception of the association between change
in OGTT and LTL in the active group when adjusted for age
(β=− 59.01, P= 0.14, 95% CI =− 138.84, 20.82). However, this
adjustment may be rendered inappropriate because age as a
covariate was non-significant in the model (β= 0.15, P= 0.73, 95%
CI =− 0.73, 1.03).
DISCUSSION
The conceptual framework for the parent study was based on a
model wherein treatment of underlying IR in patients with non-
remitted depression will improve treatment outcome. In this
report, we assessed LTL as a predictor of treatment outcome.
The main finding in this study was significant association
between the LTL and antidepressant response in active arm, but
not in placebo arm in persons with unremitted depression. While
there were no differences in LTL between IR and IS subjects at
baseline, LTL strongly predicted change in insulin sensitivity in
both active and placebo arm. While the correlation between LTL
and change in depression severity, as well as correlation with
baseline IR was significant, the strength of correlation was
stronger between LTL and antidepressant response. The lack of
differences between active and placebo arms for changes in IR
suggests that LTL predicts an improvement not specific to the
insulin-sensitizing mechanism, but possibly another, for example,
anti-inflammatory mechanism of PPAR-γ agonist. Contrary to our
non-significant findings, a significant negative correlation was
reported between LTL and HOMA-IR in patients with impaired
glucose tolerance35 and newly diagnosed type 2 diabetes.36 It is
possible that this difference is accounted for by the fact that our
subjects were at earlier stages of IR, and that negative correlation
becomes apparent when glucose dysregulation becomes more
advanced.
Two independent risk factors for accelerated aging telomere
shortening and IR have been associated with chronic depressive
illness.14,37 The role of LTL in relation to depressive disorders has
been reviewed in ref. 12 with some36,38 but not all39,40 studies
suggesting reduced LTL in treated and untreated depressed
patients. Unlike some larger studies,9 but similar to some other
studies,26,41 we did not find an association between depression
severity and LTL. Unlike Wolkowitz et al.37 and Verhoeven et al.,9
we did not find a negative association between LTL and chronicity
of depressive disorder. However, our sample was smaller, and
while Verhoeven et al.9 assessed chronicity via duration of
Table 1. Baseline demographic characteristics by treatment arm
Active (N= 22) Placebo (N=20) t-test of group differences (N= 42)
Mean 95% CI Mean 95% CI t P
Age 49.42 42.14–56.70 43.28 37.41–49.14 1.61 0.12
BMI 29.98 27.82–33.84 30.04 27.44–35.16 − 0.19 0.85
Fasting plasma glucosea 97.25 90.71–103.40 96.90 93.82–102.57 0.10 0.92
Leukocyte telomere lengtha 0.87 0.79–0.95 0.99 0.93–1.08 − 2.48 0.02
HOMAa 3.14 2.00–3.58 3.11 2.45–4.38 0.05 0.96
Oral glucose tolerance testa 103.88 91.23–110.62 131.6 107.07–166.43 −2.07 0.05
Baseline HDRS-21 16.73 14.60–19.93 14.55 8.25–14.09 1.43 0.16
Abbreviations: BMI, body mass index; CI, confidence interval. aMissing data were imputed using fully conditional specification regression. bBolded values
significant at Po0.05.
Figure 1. Change in HDRS-21 score in the active arm by LTL.
HDRS-21, Hamilton Depression Rating Scale 21 Items; LTL, leukocyte
telomere length.
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depressive episode, this study assessed number of episodes
longer than 6 months in duration.
Similar to our results, Wolkowitz et al.42 found an association
between telomerase and antidepressant response to psychotropic
agents. We observed an inverse association between baseline LTL
and change in HDRS-21 score in the active (PPAR-γ agonist), but
not in placebo arm. To the contrary, Hartmann et al.26 found no
correlation between LTL and response to treatment of depression.
The difference between the Hartmann study and ours may be due
to the choice of treatment agents (antidepressants vs PPAR-γ
agonist), duration of treatment and study design (open label vs
placebo controlled).
Understanding the role of biomarkers in accelerated aging for
prediction of response to treatment of depression is based on a
fundamental biological premise of shortened life span as a result
of environmental insults such as stress, major somatic and
psychiatric illnesses. Among the most common mediators of
accelerated aging in depressive disorders is metabolic dysfunc-
tion, for example, IR, inflammation and oxidative stress. Chronic
exposure to inflammatory cytokines, oxidative stress and
glucocorticoids may also accelerate telomere shortening.37 IR is
a proinflammatory state and is in turn associated with oxidative
stress. Our results suggest that both IR and inflammation may
mediate an antidepressant response to PPAR-γ agonist, as both IR
and IS at baseline subjects exhibited improvement in depression
severity.19
A major limitation was the small sample size, rendering these
findings preliminary. The innovative choice of therapeutic agent,
placebo-controlled design and well-described IR are among
unique features of this study. Our results augment current
understanding of the mechanisms of antidepressant response,
and, if replicated in larger samples, will aid in predicting treatment
outcome in a depressive disorder.
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